Pricing Log in Create free account

BioMarin Pharmaceutical Inc. (BMRN) vs TG Therapeutics, Inc. (TGTX)

BioMarin Pharmaceutical Inc. and TG Therapeutics, Inc. are both Biotechnology companies. BioMarin Pharmaceutical Inc. is the larger, with a market value of $10.9B against $8.9B — 1.2× the size. BioMarin Pharmaceutical Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.1×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against 18.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −0.52%) and the higher return on invested capital (10.7% vs 0.73%). Across the 21 metrics below, TG Therapeutics, Inc. leads on 12 and BioMarin Pharmaceutical Inc. on 9.

Valuation

Metric BMRN TGTX Biotechnology median
P/E n/m 19.11 10.26
P/S 2.97 10.30 9.18
P/B 1.74 13.64 2.05
Price to free cash flow 19.96 473.79 24.81
EV/EBITDA 38.25 62.00 0.65
EV/Sales 3.91 10.54 8.98
Earnings yield (0.17%) 5.23% (34.89%)
Free cash flow yield 5.01% 0.21% (24.52%)

Profitability

Metric BMRN TGTX Biotechnology median
Gross margin 75.95% 82.37% 65.16%
Operating margin 3.12% 17.05% 0.00%
Net margin (0.52%) 55.22% 0.00%
Free cash flow margin 15.26% 2.17% 0.00%
Return on equity (0.31%) 100.28% (50.12%)
Return on assets (0.20%) 37.70% (45.60%)
Return on invested capital 0.73% 10.69% 0.00%

Growth

Metric BMRN TGTX Biotechnology median
Revenue growth (TTM) 18.14% 76.08% 6.26%
EPS growth (last fiscal year) (18.55%) 1,746.67% 29.88%
Revenue growth, 5-year CAGR 11.60% 426.73% 9.75%
Net income growth, 5-year CAGR (16.39%) 0.00% 0.00%

Health

Metric BMRN TGTX Biotechnology median
Debt to equity 0.67 1.23 0.00
Current ratio 2.44 4.27 4.89
Net debt to EBITDA (1.99) 0.86 1.01

Dividend

Metric BMRN TGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BMRN TGTX Biotechnology median
Market cap 10.87b 8.87b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack